Glucagon: A Literature Course in Six Modules

This six-module course summarises what the peer-reviewed literature reports about glucagon, a pancreatic peptide hormone that has been studied for more than a century. Each module describes published work in the past tense and closes with the limits of that evidence. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or hormone. Nothing here is a protocol, and no outcome is presented as something a reader should expect.

Module 1: What Glucagon Is and How It Has Been Studied

Glucagon is a single-chain peptide of 29 amino acids cleaved from the precursor protein proglucagon. Reviews described it as the principal counter-regulatory partner to insulin, released chiefly from alpha cells of the pancreatic islets when circulating glucose falls, and acting predominantly on the liver (PMID 12626323). A centenary review in Diabetologia traced the hormone from its discovery as a hyperglycaemic contaminant of early insulin preparations through to modern receptor pharmacology, and researchers framed the next century of work around glucagon's broader metabolic roles (PMID 37367959).

Class and origin

By class, glucagon belongs to the proglucagon-derived peptide family, which also includes the glucagon-like peptides. A 2023 commentary in Peptides discussed several recurring technical and conceptual issues in this family, including how glucagon peptides are defined, measured and interpreted across studies (PMID 36521797). Tissue-specific processing of proglucagon is one reason the same gene yields different peptides in pancreas and intestine, and reviews of extrapancreatic glucagon examined evidence that glucagon-like immunoreactivity persists in people without a pancreas, raising questions about gut-derived sources (PMID 29944966).

How it has been studied

Published work on glucagon has used isolated perfused liver preparations, rodent genetic models of receptor loss, islet and alpha-cell physiology, clamp studies in humans, and pharmacological trials of agonists and antagonists, as summarised in a 2022 Cell Metabolism review of glucagon's past, present and future pharmacology (PMID 36323234). A 2024 review in Endocrinology and Metabolism covered glucagon's physiological and pharmacological functions alongside its pathophysiological significance in type 2 diabetes, where alpha-cell behaviour has been studied as a contributor to hyperglycaemia (PMID 38417825).

Limits of the evidence in Module 1: definitional and assay problems recur throughout this literature. Older immunoassays cross-reacted with related proglucagon products, and the Peptides commentary noted that interpretation of glucagon measurements depends heavily on methodology (PMID 36521797). The extrapancreatic glucagon question was described as unresolved rather than settled (PMID 29944966).

Module 2: Mechanism as Described in the Literature

Reviews describe glucagon as signalling through the glucagon receptor, a class B G-protein-coupled receptor expressed densely in hepatocytes, with canonical coupling to adenylate cyclase, cyclic AMP and protein kinase A. In the liver, researchers reported that this cascade stimulates glycogenolysis and gluconeogenesis while suppressing glycogen synthesis, producing the hormone's classical glucose-raising action (PMID 12626323).

Beyond glucose

A 2024 Physiological Reviews article titled "Hepatic glucagon action: beyond glucose mobilization" summarised evidence that hepatic glucagon signalling also governs amino acid catabolism and ureagenesis, linking alpha-cell secretion to the liver–alpha-cell axis (PMID 38300523). Work on lipid handling reported that glucagon receptor signalling influences hepatic fatty acid oxidation, lipolysis and triglyceride export, which is why lipid endpoints appear repeatedly in receptor-manipulation studies (PMID 31068828).

Energy expenditure has been a separate mechanistic thread: a 2019 review in the International Journal of Molecular Sciences collected evidence that glucagon regulates energy expenditure through central and peripheral routes, including effects attributed to thermogenic tissue and to hepatic substrate cycling (PMID 31671603). A 2021 Comprehensive Physiology review integrated these strands, describing glucagon's metabolic action across glucose, lipid and protein metabolism in health and in disease states (PMID 33792899).

Regulation of secretion

Alpha-cell secretion is itself regulated by glucose, paracrine islet signals and autonomic input. A 2026 Nature Metabolism study reported that antecedent hypoglycaemia impaired subsequent glucagon secretion by enhancing somatostatin-mediated negative feedback control within the islet (PMID 41530286). That mechanism was offered as one explanation for blunted counter-regulation after repeated low-glucose exposure.

Limits of the evidence in Module 2: much of the mechanistic detail derives from rodent tissue, isolated islets and receptor knockout models, and the reviews themselves flag translation gaps between species and between physiological and pharmacological receptor occupancy (PMID 36323234). Mechanistic plausibility in a model is not an outcome in a person.

Module 3: Reported Outcomes by Study

This module summarises what the cited papers examined and what they reported, without implying benefit for any reader. Most of the verified literature consists of narrative and systematic reviews; one primary study is included.

Where outcomes have been measured in humans

The most consistently reported human outcome is the acute rise in blood glucose after exogenous glucagon administration, which underpins its long-standing emergency and diagnostic uses and was reviewed in detail in a 2024 clinical pharmacology article (PMID 38847591). Beyond that, reviews described experimental programmes in which glucagon receptor agonism was combined with incretin receptor agonism, with body weight and hepatic fat among the endpoints studied (PMID 36323234), and the centenary review discussed how those combination approaches reframed glucagon from a purely diabetogenic hormone to a pharmacological tool under investigation (PMID 37367959).

Limits of the evidence in Module 3: reviews aggregate heterogeneous studies with different species, doses and durations, and none of the cited papers established that glucagon alone improves a long-term clinical outcome in otherwise healthy people. Endpoints such as energy expenditure were measured in controlled experimental settings, not as durable real-world results (PMID 31671603).

Module 4: Glucagon Side Effects: What Studies Report

Adverse events in this literature fall into three published groupings: acute effects of exogenous glucagon, metabolic consequences of sustained receptor activation, and effects reported when the receptor was blocked.

Acute administration

The 2024 clinical pharmacology review reported that gastrointestinal effects, particularly nausea and vomiting, were the tolerability issues most consistently associated with therapeutic glucagon administration, alongside the expected transient rise in glucose (PMID 38847591). Reviews of glucagon pharmacology also noted that its smooth-muscle relaxant effect, exploited diagnostically in gastrointestinal imaging, accompanies its metabolic actions (PMID 36323234).

Sustained receptor activation

Because hepatic glucagon signalling drives amino acid catabolism and ureagenesis, reviewers discussed protein catabolism and shifts in circulating amino acids as expected consequences of sustained agonism (PMID 38300523). Hyperglycaemia itself is the principal metabolic liability: reviews of type 2 diabetes described excessive or inappropriately timed glucagon secretion as a reported driver of elevated glucose (PMID 38417825), and broader metabolic reviews placed the same concern in the context of glucagon's actions in disease (PMID 33792899).

Receptor blockade and the liver–alpha-cell axis

Researchers reviewing glucagon receptor antagonists reported hepatic and lipid liabilities, including changes in liver enzymes and circulating lipids, as reasons those programmes stalled (PMID 36323234). Reviews of glucagon receptor signalling in lipid metabolism described the same axis from the opposite direction, reporting that interrupting glucagon signalling altered hepatic lipid handling (PMID 31068828). Separately, the 2026 study reported impaired glucagon secretion after antecedent hypoglycaemia, a defect relevant to counter-regulatory failure rather than to exogenous dosing (PMID 41530286).

Limits of the evidence in Module 4: the verified literature is dominated by reviews, which do not report incidence rates with the rigour of a trial safety table. Long-term safety data for glucagon receptor agonism outside approved acute indications were not established in these sources (PMID 38847591).

Module 5: Pharmacokinetics Where Data Exist

Glucagon is a peptide and is degraded in the gastrointestinal tract, so published clinical pharmacology concerns parenteral and mucosal routes. The 2024 Clinical Pharmacology and Therapeutics review summarised absorption, distribution, metabolism and elimination for available glucagon formulations and discussed how formulation chemistry shaped the speed and duration of the glycaemic response (PMID 38847591). Native glucagon has a short circulating half-life, and reviewers described this instability as the central pharmacokinetic constraint that motivated stabilised analogues and soluble formulations (PMID 36323234).

Clearance is primarily hepatic and renal, and reviews of hepatic glucagon action emphasised that the liver is both the main target organ and a major site of extraction, so hepatic status affects exposure and response (PMID 38300523). Measurement remains a practical issue: the Peptides commentary reported that assay specificity influences reported concentrations of glucagon and related proglucagon peptides (PMID 36521797).

Limits of the evidence in Module 5: pharmacokinetic parameters vary by formulation, route and assay, and none of the cited reviews provided a single set of values that generalises across products or populations (PMID 38847591). No page can substitute for a specific product's approved labelling.

Module 6: Regulatory Status, Stated Factually

Glucagon is not an investigational-only peptide. Prescription glucagon products have been approved by regulators for the emergency treatment of severe hypoglycaemia and, in some jurisdictions, as a diagnostic aid during gastrointestinal procedures because of its smooth-muscle effects; the 2024 clinical pharmacology review described these established therapeutic and diagnostic applications (PMID 38847591). Approved presentations have included injectable kits requiring reconstitution, ready-to-use liquid autoinjectors and a nasal powder, each with its own labelling.

Separately, glucagon peptide sold with "research use only" (RUO) labelling is not an approved medicine, is not manufactured or released under the controls applied to drug products, and is designated for laboratory work rather than human administration. Compounding is a distinct legal category: in the United States, compounding pharmacies operate under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which permit preparation of medicines for identified patient needs under conditions set by federal and state law, and compounded preparations are not FDA-approved products. Glucagon receptor agonists and antagonists developed as investigational drugs sit in yet another category, and reviews described several of those programmes as discontinued or still experimental rather than approved (PMID 36323234). This section is informational and is not legal advice.

Limits of the evidence in Module 6: regulatory status differs by country and changes over time, and approval for one indication says nothing about safety or efficacy for another. The centenary review framed most non-emergency glucagon applications as research directions rather than settled practice (PMID 37367959).

What the Studies Did Not Test

Across the verified literature, several questions were left open:

• No cited study tested glucagon administration for body composition, fitness or wellness purposes in healthy adults; energy expenditure work was experimental and mechanistic (PMID 31671603).
• Long-term outcome data for chronic glucagon receptor agonism as a monotherapy were not established in these reviews (PMID 36323234).
• The source and physiological role of extrapancreatic glucagon remained unresolved (PMID 29944966).
• Whether the somatostatin-mediated impairment of glucagon secretion after antecedent hypoglycaemia can be reversed clinically was not answered by the study that described it (PMID 41530286).
• Comparative safety across formulations, populations and durations of use was not systematically quantified in the cited pharmacology review (PMID 38847591).

Readers with clinical questions about hypoglycaemia, diabetes or any medication should raise them with a licensed physician; this course describes published research only.

References

• Glucagon and regulation of glucose metabolism (American Journal of Physiology. Endocrinology and Metabolism, 2003)
• 100 years of glucagon and 100 more (Diabetologia, 2023)
• Hepatic glucagon action: beyond glucose mobilization (Physiological Reviews, 2024)
• The past, present, and future physiology and pharmacology of glucagon (Cell Metabolism, 2022)
• Glucagon Receptor Signaling and Lipid Metabolism (Frontiers in Physiology, 2019)
• Glucagon's Metabolic Action in Health and Disease (Comprehensive Physiology, 2021)
• Glucagon Regulation of Energy Expenditure (International Journal of Molecular Sciences, 2019)
• Four sidenotes about glucagon peptides (Peptides, 2023)
• Extrapancreatic glucagon: Present status (Diabetes Research and Clinical Practice, 2019)
• Clinical Pharmacology of Glucagon (Clinical Pharmacology and Therapeutics, 2024)
• Glucagon: Physiological and Pharmacological Functions and Pathophysiological Significance in Type 2 Diabetes (Endocrinology and Metabolism, 2024)
• Antecedent hypoglycaemia impairs glucagon secretion by enhancing somatostatin-mediated negative feedback control (Nature Metabolism, 2026)